Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 41, 2009, Pages 17481-17486

  Gallorini, Simona ^a   Berti, Francesco ^a   Mancuso, Giuseppe ^b   Cozzi, Roberta ^a   Tortoli, Marco ^a   Volpini, Gianfranco ^a   Telford, John L ^a   Beninati, Concetta ^b   Maione, Domenico ^a   Wack, Andreas ^a,c  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Adjuvant; Dendritic cell; Group B Streptococcus

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CD4 ANTIGEN; CD86 ANTIGEN; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; N ACETYLNEURAMINIC ACID DERIVATIVE; POLYSACCHARIDE PROTEIN CRM197 CONJUGATE VACCINE; POLYSACCHARIDE PROTEIN HSA CONJUGATE VACCINE; POLYSACCHARIDE VACCINE; PROTEIN HSA; RANTES; TETANUS TOXOID; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZWITTERIONIC POLYSACCHARIDE; ZWITTERIONIC POLYSACCHARIDE PROTEIN CRM197 CONJUGATE VACCINE; ZWITTERIONIC POLYSACCHARIDE PROTEIN HSA CONJUGATE VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG ANTIGENICITY; DRUG CONJUGATION; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GROUP B STREPTOCOCCAL INFECTION; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; MOTHER; MOUSE; NEWBORN; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGENY; SPLEEN CELL; T LYMPHOCYTE; VACCINATION;

ANIMALS; BACTERIAL VACCINES; HUMANS; INFANT, NEWBORN; MICE; POLYSACCHARIDES; STREPTOCOCCAL INFECTIONS; TOLL-LIKE RECEPTOR 2; VACCINES, CONJUGATE;

MUS; STREPTOCOCCUS SP. 'GROUP B';

EID: 70350440469     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0903313106     Document Type: Article

References (40)

1. Weintraub A (2003) Immunology of bacterial polysaccharide antigens. Carbohydr Res 338:2539-2547.
2. Lesinski GB, Westerink MA (2001) Novel vaccine strategies to T-independent antigens. J Microbiol Methods 47:135-149.
3. Paoletti LC, Kasper DL (2003) Glycoconjugate vaccines to prevent group B streptococcal infections. Expert Opin Biol Ther 3:975-984. (Pubitemid 37093152)
4. Paoletti LC, et al. (2001) Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 69:6696-6701.
5. Guttormsen HK, Wetzler LM, Finberg RW, Kasper DL (1998) Immunologic memory induced by a glycoconjugate vaccine in amurine adoptive lymphocyte transfer model. Infect Immun 66:2026-2032.
6. Paoletti LC, Kennedy RC, Chanh TC, Kasper DL (1996) Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons. Infect Immun 64:677-679. (Pubitemid 26032849)
7. Kalka-Moll WM, et al. (2002) Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. J Immunol 169:6149-6153.
8. Stephen TL, et al. (2005) Effect of B7-2 and CD40 signals from activated antigen-presenting cells on the ability of zwitterionic polysaccharides to induce T-cell stimulation. Infect Immun 73:2184-2189.
9. Tzianabos AO, et al. (1992) The capsular polysaccharide of Bacteroides fragilis comprises two ionically linked polysaccharides. J Biol Chem 267:18230-18235.
10. Tzianabos AO, Kasper DL, Onderdonk AB (1995) Structure and function of Bacteroides fragilis capsular polysaccharides: Relationship to induction and prevention of abscesses. Clin Infect Dis 20 Suppl 2:S132-140.
11. Wang Q, et al. (2006) A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med 203:2853-2863. (Pubitemid 46026163)
12. Stingele F, et al. (2004) Zwitterionic polysaccharides stimulate T cells with no preferential V beta usage and promote anergy, resulting in protection against experimental abscess formation. J Immunol 172:1483-1490. (Pubitemid 38116791)
13. Wang B, et al. (2007) A Toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol 14:902-906.
14. Jackson DC, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 101:15440-15445.
15. Chua BY, Zeng W, Jackson DC (2008) Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines. Methods Mol Biol 494:247-261.
16. Gallorini S, et al. (2007) Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J Immunol 179:8208-8215.
17. Wessels MR, et al. (1990) Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest 86:1428-1433. (Pubitemid 20372587)
18. Latz E, Franko J, Golenbock DT, Schreiber JR (2004) Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol 172:2431-2438. (Pubitemid 38182392)
19. Rodewald AK, Onderdonk AB, Warren HB, Kasper DL (1992) Neonatal mouse model of group B streptococcal infection. J Infect Dis 166:635-639.
20. Tzianabos AO, Onderdonk AB, Rosner B, Cisneros RL, Kasper DL (1993) Structural features of polysaccharides that induce intra-abdominal abscesses. Science 262:416-419. (Pubitemid 23353382)
21. Kalka-Moll WM, et al. (2000) Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity. J Immunol 164:719-724.
22. Tzianabos AO, Onderdonk AB, Smith RS, Kasper DL (1994) Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect Immun 62:3590-3593.
23. Mellman I, Steinman RM (2001) Dendritic cells: Specialized and regulated antigen processing machines. Cell 106:255-258. (Pubitemid 32772607)
24. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621-667. (Pubitemid 34293436)
25. Medzhitov R, Janeway CA, Jr (1998) Innate immune recognition and control of adaptive immune responses. Semin Immunol 10:351-353.
26. Palm NW, Medzhitov R (2009) Pattern recognition receptors and control of adaptive immunity. Immunol Rev 227:221-233.
27. Querec T, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413-424. (Pubitemid 43290850)
28. Sen G, Khan AQ, Chen Q, Snapper CM (2005) In vivo humoral immune responses to isolated pneumococcal polysaccharides are dependent on the presence of associated TLR ligands. J Immunol 175:3084-3091. (Pubitemid 41170528)
29. Khan S, et al. (2007) Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 282:21145-21159. (Pubitemid 47099911)
30. Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003) Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197:1107-1117. (Pubitemid 36570066)
31. Mukhopadhyay S, Herre J, Brown GD, Gordon S (2004) The potential for Toll-like receptors to collaborate with other innate immune receptors. Immunology 112:521-530. (Pubitemid 39061476)
32. Dennehy KM, et al. (2008) Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol 38:500-506.
33. Steinman RM, Pope M (2002) Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109:1519-1526.
34. Boscardin SB, et al. (2006) Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 203:599-606.
35. Bertozzi CR, Kiessling LL (2001) Chemical glycobiology. Science 291:2357-2364.
36. Jennings HJ, Roy R, Gamian A (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 137:1708-1713. (Pubitemid 16014828)
37. Ashton FE, Ryan JA, Michon F, Jennings HJ (1989) Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microb Pathog 6:455-458. (Pubitemid 19223600)
38. Guttormsen HK, et al. (2008) Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching. Proc Natl Acad Sci USA 105:5903-5908.
39. Takeuchi O, et al. (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443-451. (Pubitemid 29504199)
40. Lutz MB, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223:77-92.